FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044939920> ?p ?o ?g. }

• W3044939920 endingPage "2" @default.
• W3044939920 startingPage "1" @default.
• W3044939920 abstract "In 2013, Calabrese et al. described the effectiveness of early 20th century radiotherapy to treat viral and bacterial pneumonia patients, citing a cure rate of ∼80%.1.Calabrese EJ Dhawan G How radiotherapy was historically used to treat pneumonia: Could it be useful today?.Yale J. Biol. Med. 2013; 86: 555-570PubMed Google Scholar These were single fraction treatments of 30 to 100 cGy dose delivered with 100 to 200 kVp x-rays. These treatments stopped in the 1940s due to the availability of antibiotics and steroids, but in light of the lack of effective treatment options for COVID-19, radiotherapy could offer a viable and immediate option2.Kirkby C Mackenzie M Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?.Radiother. Oncol. 2020; (https://doi.org/)https://doi.org/10.1016/j_radonc.2020.04.004Crossref Google Scholar,3.Dhawan G Kapoor R Dhawan R et al.Low dose radiation therapy as a potential life-saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS).Radiother. Oncol. 2020; (https://doi.org/)https://doi.org/10.1016/j_radonc.2020.05.002Crossref PubMed Google Scholar until a more effective cure becomes available. A low-dose radiotherapy to whole lung can be easily delivered with a linear accelerator (linac). However, transportation of an infected patient, who may be intubated, from the intensive care unit (ICU) to the radiation oncology clinic and back, could pose an imminent risk of viral spread and contamination. Cancer patients undergoing treatment, in addition to radiation oncology staff, could end up infected despite rigourous procedure protocols. Many cancer patients are immunocompromised, which amplifies the risk of sharing spaces with COVID-19 patients. An alternative could be the use of fluoroscopy equipment to deliver a radiotherapy treatment similar to the historical treatments. X-ray energies comparable to those for which biological effectiveness was demonstrated in the past can be produced with modern fluoroscopes (e.g., fixed and mobile c-arms). C-arms are more widely available than linacs, especially in developing countries, and could be used to deliver a treatment in-situ and/or with minimal transportation to a procedure room. Elderly patients (50 yo <) infected with the COVID-19 virus and at high risk of death, could be irradiated to low doses (30 to 50 cGy to the lung) using a c-arm system. The benefit-to-risk ratio of radiotherapy is particularly high for this patient population, who are less likely to develop secondary cancers due to reduced radiosensitivity. The treatment could be performed in the ICU or emergency room without the need to transport the patient to a radiation oncology clinic. Although a more in-depth investigation would be needed, it can be speculated that delivery of a 30 to 50 cGy dose to the lungs could pose little risk of detriment and/or secondary cancers, especially in elderly patients.4.Tubiana M Diallo I Chavaudra J et al.A new method of assessing the dose-carcinogenic effect relationship in patients exposed to ionizing radiation. A concise presentation of preliminary data.Health Phys. 2011; 100: 296-299Crossref PubMed Google Scholar Preliminary computer simulations (under peer review) have suggested that the doses delivered to other radiosensitive tissues exposed by this treatment could be within the range seen in cardiac interventional procedures, with skin doses around 200 to 300 cGy and cardiac doses around 50 cGy.5.Uniyal SC Chatuverdi V Sharma SD et al.Patient dosimetry during interventional cardiac procedure in a dedicated catherization laboratory.Radiat. Prot. Dosim. 2017; 356 175: 201-208Google Scholar Finally, the cost of treating COVID-19 patients with radiation could be cheaper and potentially more effective than with well-publicized experimental drugs. For instance, in the United States, it would cost over $3000 per treatment course for infected patients to be treated with remdesevir, even though the drug was shown to slightly reduce recovery time but not mortality.6.Remdesivir KG. The first coronavirus drug, gets a price tag.N. Y. Times Health. 2020; (Available at)https://www.nytimes.com/2020/06/29/health/coronavirus-remdesivir-gilead.htmGoogle Scholar A dedicated c-arm could treat multiple patients per day at minimal cost, which would improve treatment options for underinsured patients or those in low-income and developing countries." @default.
• W3044939920 created "2020-07-29" @default.
• W3044939920 creator A5000614222 @default.
• W3044939920 creator A5006592291 @default.
• W3044939920 creator A5011365706 @default.
• W3044939920 creator A5012076668 @default.
• W3044939920 creator A5023195809 @default.
• W3044939920 creator A5024861380 @default.
• W3044939920 creator A5032005399 @default.
• W3044939920 creator A5044074623 @default.
• W3044939920 creator A5061016797 @default.
• W3044939920 creator A5063943448 @default.
• W3044939920 creator A5068178702 @default.
• W3044939920 creator A5069559270 @default.
• W3044939920 creator A5070495377 @default.
• W3044939920 creator A5078601222 @default.
• W3044939920 creator A5080240115 @default.
• W3044939920 creator A5086467800 @default.
• W3044939920 date "2021-01-01" @default.
• W3044939920 modified "2023-10-15" @default.
• W3044939920 title "Rationale for using a C-arm fluoroscope to deliver a kilovoltage radiotherapy treatment to COVID-19 patients" @default.
• W3044939920 cites W2049008014 @default.
• W3044939920 cites W3023031064 @default.
• W3044939920 doi "https://doi.org/10.1016/j.meddos.2020.07.008" @default.
• W3044939920 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7381930" @default.
• W3044939920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32878727" @default.
• W3044939920 hasPublicationYear "2021" @default.
• W3044939920 type Work @default.
• W3044939920 sameAs 3044939920 @default.
• W3044939920 citedByCount "3" @default.
• W3044939920 countsByYear W30449399202021 @default.
• W3044939920 countsByYear W30449399202022 @default.
• W3044939920 crossrefType "journal-article" @default.
• W3044939920 hasAuthorship W3044939920A5000614222 @default.
• W3044939920 hasAuthorship W3044939920A5006592291 @default.
• W3044939920 hasAuthorship W3044939920A5011365706 @default.
• W3044939920 hasAuthorship W3044939920A5012076668 @default.
• W3044939920 hasAuthorship W3044939920A5023195809 @default.
• W3044939920 hasAuthorship W3044939920A5024861380 @default.
• W3044939920 hasAuthorship W3044939920A5032005399 @default.
• W3044939920 hasAuthorship W3044939920A5044074623 @default.
• W3044939920 hasAuthorship W3044939920A5061016797 @default.
• W3044939920 hasAuthorship W3044939920A5063943448 @default.
• W3044939920 hasAuthorship W3044939920A5068178702 @default.
• W3044939920 hasAuthorship W3044939920A5069559270 @default.
• W3044939920 hasAuthorship W3044939920A5070495377 @default.
• W3044939920 hasAuthorship W3044939920A5078601222 @default.
• W3044939920 hasAuthorship W3044939920A5080240115 @default.
• W3044939920 hasAuthorship W3044939920A5086467800 @default.
• W3044939920 hasBestOaLocation W30449399201 @default.
• W3044939920 hasConcept C126322002 @default.
• W3044939920 hasConcept C141071460 @default.
• W3044939920 hasConcept C2776256026 @default.
• W3044939920 hasConcept C2776348555 @default.
• W3044939920 hasConcept C2777714996 @default.
• W3044939920 hasConcept C2777914695 @default.
• W3044939920 hasConcept C2779134260 @default.
• W3044939920 hasConcept C2989005 @default.
• W3044939920 hasConcept C2992520072 @default.
• W3044939920 hasConcept C3008058167 @default.
• W3044939920 hasConcept C509974204 @default.
• W3044939920 hasConcept C524204448 @default.
• W3044939920 hasConcept C71924100 @default.
• W3044939920 hasConceptScore W3044939920C126322002 @default.
• W3044939920 hasConceptScore W3044939920C141071460 @default.
• W3044939920 hasConceptScore W3044939920C2776256026 @default.
• W3044939920 hasConceptScore W3044939920C2776348555 @default.
• W3044939920 hasConceptScore W3044939920C2777714996 @default.
• W3044939920 hasConceptScore W3044939920C2777914695 @default.
• W3044939920 hasConceptScore W3044939920C2779134260 @default.
• W3044939920 hasConceptScore W3044939920C2989005 @default.
• W3044939920 hasConceptScore W3044939920C2992520072 @default.
• W3044939920 hasConceptScore W3044939920C3008058167 @default.
• W3044939920 hasConceptScore W3044939920C509974204 @default.
• W3044939920 hasConceptScore W3044939920C524204448 @default.
• W3044939920 hasConceptScore W3044939920C71924100 @default.
• W3044939920 hasIssue "1" @default.
• W3044939920 hasLocation W30449399201 @default.
• W3044939920 hasLocation W30449399202 @default.
• W3044939920 hasLocation W30449399203 @default.
• W3044939920 hasOpenAccess W3044939920 @default.
• W3044939920 hasPrimaryLocation W30449399201 @default.
• W3044939920 hasRelatedWork W2000956038 @default.
• W3044939920 hasRelatedWork W3019584948 @default.
• W3044939920 hasRelatedWork W3157949845 @default.
• W3044939920 hasRelatedWork W3158742495 @default.
• W3044939920 hasRelatedWork W3193110114 @default.
• W3044939920 hasRelatedWork W4210777482 @default.
• W3044939920 hasRelatedWork W4244652115 @default.
• W3044939920 hasRelatedWork W4283166058 @default.
• W3044939920 hasRelatedWork W4288358222 @default.
• W3044939920 hasRelatedWork W4214780115 @default.
• W3044939920 hasVolume "46" @default.
• W3044939920 isParatext "false" @default.
• W3044939920 isRetracted "false" @default.
• W3044939920 magId "3044939920" @default.
• W3044939920 workType "article" @default.